Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy versus triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK

Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy versus triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK

Chris Kiff,1 Sandrine Ruiz,2 Nebibe Varol,3 Danny Gibson,4 Andrew Davies,1 Debasree Purkayastha5 1ICON plc, Abingdon, UK; 2AstraZeneca, Barcelona, Spain; 3AstraZeneca, Cambridge, UK; 4AstraZeneca, Luton, UK; 5Phastar, Manchester, UK Purpose: Patients with severe COPD are at high risk of experienci...

Full description

Bibliographic Details
Main Authors: Kiff C, Ruiz S, Varol N, Gibson D, Davies A, Purkayastha D
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:International Journal of COPD
Subjects:
National Health Service
National Institute of Clinical Excellence
exacerbation rates
Online Access:https://www.dovepress.com/cost-effectiveness-of-roflumilast-as-an-add-on-to-triple-inhaled-thera-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/cost-effectiveness-of-roflumilast-as-an-add-on-to-triple-inhaled-thera-peer-reviewed-article-COPD

Similar Items